• Resources
  • Case Studies
  • Comparing clinical response rates for Tumor Infiltrating Lymphocytes against other therapeutic modalities


Alacrita supported the European arm of a major company creation investor as part of an ongoing workstream to evaluate the benefits of refocusing its investments into the tumour infiltrating (TILs) space. Following a clinical landscape analysis performed by Alacrita, the investor commissioned us to provide competitive intelligence around TILs technology in key cancer indications.


Alacrita performed a clinical comparison analysis of pipeline TIL technologies against standard of care and non-TIL clinical candidates in eleven cancer indications. Our analysts used proprietary databases and public literature sources to create a large database of clinical data for products in each cancer indication, covering all therapeutic modalities. Outcomes measures (CR, PR, DoR, PFS, OS) were quantitatively compared against those for TILs products; we provided the database and our subsequent analysis to the client for use in its investment case.

Strategy & Commercialization

Our team of expert pharmaceutical business consultants provides deep knowledge in critical areas such as company and portfolio strategies, fundraising pitch materials, platform or program opportunity-feasibility assessments, new product planning, value-based pricing and market access, and product launch preparations.

Related Case Studies